A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors [0.03%]
关于新药navicixizumab(Omp-305b83)治疗实体瘤的首次人体1a期临床试验
Antonio Jimeno,Kathleen N Moore,Michael Gordon et al.
Antonio Jimeno et al.
Purpose Navicixizumab (OMP-305B83) is a bispecific antibody that inhibits delta-like ligand 4 and vascular endothelial growth factor. This Phase 1a trial assessed escalating doses of navicixizumab in refractory solid tumors patients. Design...
Clinical Trial
Investigational new drugs. 2019 Jun;37(3):461-472. DOI:10.1007/s10637-018-0665-y 2019
Identification of differentially expressed genes and signaling pathways using bioinformatics in interstitial lung disease due to tyrosine kinase inhibitors targeting the epidermal growth factor receptor [0.03%]
生物信息学在表皮生长因子受体酪氨酸激酶抑制剂所致间质性肺疾病中差异表达基因及信号通路中的应用分析
Yuan Lu,Ang Li,Xiaofeng Lai et al.
Yuan Lu et al.
Interstitial lung disease (ILD) is a rare but lethal adverse effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) treatment. The specific mechanism of this disease is not fully understood. To systematically an...
Novel N-1 substituted fluoroquinolones inhibit human topoisomerase I activity and exhibit anti-proliferative activity [0.03%]
新的N-1取代的氟喹诺酮抑制人拓扑异构酶I活性并表现出抗增殖作用
Lisa M Oppegard,Justine L Delgado,Chaitanya A Kulkarni et al.
Lisa M Oppegard et al.
Fluoroquinolone-class agents selectively target the bacterial type IIA topoisomerases DNA gyrase and topoisomerase IV, with a few exceptions that target eukaryotic type IIA topoisomerases. Fluoroquinolones bind and stabilize type IIA topois...
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients [0.03%]
索拉非尼联合雷西莫司特（一种口服型HDAC抑制剂）对比单用索拉非尼一线治疗亚洲晚期肝细胞癌患者的I/II期研究
Won Young Tak,Baek-Yeol Ryoo,Ho Yeong Lim et al.
Won Young Tak et al.
Purpose: Resminostat is an oral inhibitor of class I, IIB, and IV histone deacetylases. This phase I/II study compared the safety and efficacy of resminostat plus sorafenib versus sorafenib monotherapy as first-line thera...
CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia [0.03%]
CDKI-73：一种口服生物可利用的高效急性髓系白血病CDK9抑制剂
Muhammed H Rahaman,Yingyi Yu,Longjin Zhong et al.
Muhammed H Rahaman et al.
Acute myeloid leukemia (AML) is the most common form of acute leukemia with dismal long-term prognosis with age. The most aggressive subtype of AML is MLL-AML that is characterized by translocations of the mixed-lineage leukemia gene (MLL) ...
Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study [0.03%]
酮康唑联合来那度胺治疗去势抵抗性前列腺癌（CRPC）的开放性II期临床研究结果
Pedro C Barata,Matthew Cooney,Prateek Mendiratta et al.
Pedro C Barata et al.
Introduction Ketoconazole is CYP-17 inhibitor with demonstrated activity in men with castration-resistant prostate cancer (CRPC). Lenalidomide is an antiangiogenic and immunomodulatory agent with broad antitumor activity. We hypothesized th...
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer [0.03%]
alisertib联合mFOLFOX方案治疗胃肠癌的I期临床研究
Laura W Goff,Nilofer S Azad,Stacey Stein et al.
Laura W Goff et al.
Overexpression and cellular mis-localization of aurora kinase A (AURKA) in gastrointestinal cancers results in chromosomal instability, activation of multiple oncogenic pathways, and inhibition of pro-apoptotic signaling. Inhibition of AURK...
Clinical Trial
Investigational new drugs. 2019 Apr;37(2):315-322. DOI:10.1007/s10637-018-0663-0 2019
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors [0.03%]
Tipifarnib联合表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼治疗晚期实体瘤I期临床研究
Khalid Jazieh,Julian Molina,Jacob Allred et al.
Khalid Jazieh et al.
Introduction Based on preclinical cytotoxic synergy between tipifarnib and erlotinib, a phase I study of this combination was conducted in patients with advanced solid tumors to evaluate safety, tolerability, maximum tolerated dose (MTD) an...
Clinical Trial
Investigational new drugs. 2019 Apr;37(2):307-314. DOI:10.1007/s10637-018-0662-1 2019
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma [0.03%]
组蛋白去乙酰化酶抑制剂quisinostat治疗食管鳞状细胞癌的药效学评估研究
Lei Zhong,Shu Zhou,Rongsheng Tong et al.
Lei Zhong et al.
Esophageal squamous cell carcinoma (ESCC) is one of the most serious life-threatening malignancies. Although chemotherapeutic targets and agents for ESCC have made much progress recently, the efficacy is still unsatisfactory. Therefore, the...
Hexane partition from Annona crassiflora Mart. promotes cytotoxity and apoptosis on human cervical cancer cell lines [0.03%]
安诺纳粗果亚麻醇提物的己烷部分通过促进细胞毒性及凋亡作用抑制人宫颈癌细胞系的生长
Viviane A O Silva,Ana Laura V Alves,Marcela N Rosa et al.
Viviane A O Silva et al.
Cervical cancer is the third most commonly diagnosed tumor type and the fourth cause of cancer-related death in females. Therapeutic options for cervical cancer patients remain very limited. Annona crassiflora Mart. is used in traditional m...